{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T01:33:38Z","timestamp":1784424818015,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373894"],"award-info":[{"award-number":["82373894"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304540"],"award-info":[{"award-number":["82304540"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.115908","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:46:42Z","timestamp":1764092802000},"page":"115908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P2","title":["Targeting PDPN+ CAFs enhances treatment efficacy of trastuzumab by reversing immunosuppressive microenvironment in HER2-positive breast cancer"],"prefix":"10.1016","volume":"168","author":[{"given":"Shuangpeng","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianguang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisiyao","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115908_bb0005","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2025.115908_bb0010","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2025.115908_bb0015","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00432-021-03651-1","article-title":"Trastuzumab treatment of patients with early, HER2-positive breast cancer in 17 certified German breast cancer centers","volume":"148","author":"Sibert","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115908_bb0020","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2174\/1871530321666210426125904","article-title":"Immunotherapy for breast Cancer treatment: current evidence and therapeutic options","volume":"22","author":"Singh","year":"2022","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.intimp.2025.115908_bb0025","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115908_bb0030","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast Cancer: ASCO guideline update","volume":"40","author":"Giordano","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115908_bb0035","first-page":"14","article-title":"Overcoming resistance to HER2-directed therapies in breast Cancer","author":"Schlam","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.115908_bb0040","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.ccell.2022.10.015","article-title":"CD16(+) fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition","volume":"40","author":"Liu","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115908_bb0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast Cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115908_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100947","article-title":"PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity","volume":"68","author":"Du","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.intimp.2025.115908_bb0055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-024-07698-1","article-title":"Tumour vasculature at single-cell resolution","volume":"632","author":"Pan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115908_bb0060","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/s41467-022-33052-y","article-title":"Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast","volume":"13","author":"Geldhof","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115908_bb0075","article-title":"CXCL12(+) tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma","author":"Lu","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2025.115908_bb0080","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10549-011-1457-7","article-title":"Bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer","volume":"131","author":"J\u00e9z\u00e9quel","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.intimp.2025.115908_bb0085","first-page":"15","article-title":"Photodynamic stromal depletion in pancreatic ductal adenocarcinoma","author":"Lintern","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.115908_bb0090","doi-asserted-by":"crossref","first-page":"14576","DOI":"10.1038\/s41598-018-32855-8","article-title":"Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor","volume":"8","author":"Seo","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.115908_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.devcel.2025.07.010","article-title":"The extracellular-matrix-remodeling capability exposes therapeutic vulnerability in a subset of renal cell carcinomas with tumor thrombi","author":"Zhang","year":"2025","journal-title":"Dev. Cell"},{"key":"10.1016\/j.intimp.2025.115908_bb0105","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","article-title":"Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer","volume":"42","author":"Cords","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115908_bb0110","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41419-023-06280-3","article-title":"PDPN(+) CAFs facilitate the motility of OSCC cells by inhibiting ferroptosis via transferring exosomal lncRNA FTX","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.115908_bb0115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-022-01597-7","article-title":"Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4\/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer","volume":"21","author":"Heidegger","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2025.115908_bb0120","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s13046-023-02900-0","article-title":"Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1","volume":"42","author":"Zhang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115908_bb0125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20020121","article-title":"Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase","volume":"196","author":"Frumento","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2025.115908_bb0130","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.4049\/jimmunol.168.8.3771","article-title":"Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses","volume":"168","author":"Mellor","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115908_bb0135","first-page":"132","article-title":"TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma","author":"Hu","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115908_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy - are we making headway?","author":"Reck","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115908_bb0145","first-page":"692","article-title":"Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4(+) and PDPN(+) CAFs to clinical outcome","volume":"1","author":"Friedman","year":"2020","journal-title":"Nat. Can."},{"key":"10.1016\/j.intimp.2025.115908_bb0150","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","article-title":"Activated fibroblasts in cancer: perspectives and challenges","volume":"41","author":"Caligiuri","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115908_bb0155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.trecan.2024.11.005","article-title":"Functional heterogeneity of fibroblasts in primary tumors and metastases","volume":"11","author":"Cheng","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.intimp.2025.115908_bb0160","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(22)00196-6","article-title":"Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial","volume":"23","author":"Saji","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2025.115908_bb0165","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1200\/JCO.2014.59.5298","volume":"33","author":"Rugo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115908_bb0170","article-title":"Development of Nectin4\/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115908_bb0175","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1200\/JCO.2025.43.16_suppl.3028","article-title":"First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors","volume":"43","author":"Torres-Jim\u00e9nez","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115908_bb0180","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.16958","article-title":"The relationship between cancer associated fibroblasts biomarkers and prognosis of breast cancer: a systematic review and meta-analysis","volume":"12","author":"Cui","year":"2024","journal-title":"PeerJ"},{"key":"10.1016\/j.intimp.2025.115908_bb0185","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1002\/ijc.29655","article-title":"CXCL12-CXCR7 axis is important for tumor endothelial cell angiogenic property","volume":"137","author":"Yamada","year":"2015","journal-title":"Int. J. Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501896X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501896X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:00:21Z","timestamp":1771513221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692501896X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"alternative-id":["S156757692501896X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115908","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PDPN+ CAFs enhances treatment efficacy of trastuzumab by reversing immunosuppressive microenvironment in HER2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115908"}}